Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Antipsychotics for Psychosis Syndrome
NCT02137616Unknown
- Sponsor
- Central South University
- Start
- Jun 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of risperidone, olanzapine, quetiapine and aripiprazole in psychotic disorder and Psychosis risk syndrome (CHR) (4 arms), sponsored by Central South University. Primary endpoint: Positive and Negative Syndrome Scale Total Scores at 18 months. Status: unknown.
02
Drugs
risperidoneolanzapinequetiapinearipiprazole
03
Conditions
psychotic disorderPsychosis risk syndrome (CHR)
Beyond the preview
Go deeper on NCT02137616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137616.